RRR

READ-GENE

No trades
See on Supercharts
Market capitalization
‪59.19 M‬PLN
−0.08PLN
‪−1.35 M‬PLN
‪10.15 M‬PLN
Beta (1Y)
0.15
Employees (FY)
29
Change (1Y)
+2 +7.41%
Revenue / Employee (1Y)
‪88.74 K‬PLN
Net income / Employee (1Y)
‪−11.77 K‬PLN

About READ-GENE


CEO
Jan Lubinski
Headquarters
Dobra
Founded
2005
ISIN
PLRADGN00014
FIGI
BBG000KYH0P6
Read-Gene SA engages in the medical research and testing. It develops cancer prevention treatment based on genetic tests. The company was founded on September 27, 2005 and is headquartered in Dobra, Poland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RDG is 5.00 PLN — it has decreased by −0.40% in the past 24 hours. Watch READ-GENE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NEWCONNECT exchange READ-GENE stocks are traded under the ticker RDG.
RDG stock has risen by 1.21% compared to the previous week, the month change is a −11.97% fall, over the last year READ-GENE has showed a 57.23% increase.
RDG reached its all-time high on Dec 11, 2023 with the price of 7.80 PLN, and its all-time low was 0.38 PLN and was reached on Dec 21, 2018. View more price dynamics on RDG chart.
See other stocks reaching their highest and lowest prices.
RDG stock is 0.40% volatile and has beta coefficient of 0.15. Track READ-GENE stock price on the chart and check out the list of the most volatile stocks — is READ-GENE there?
Today READ-GENE has the market capitalization of ‪59.19 M‬, it has increased by 1.41% over the last week.
Yes, you can track READ-GENE financials in yearly and quarterly reports right on TradingView.
RDG net income for the last quarter is ‪−300.13 K‬ PLN, while the quarter before that showed ‪−534.91 K‬ PLN of net income which accounts for 43.89% change. Track more READ-GENE financial stats to get the full picture.
No, RDG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 29.00 employees. See our rating of the largest employees — is READ-GENE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. READ-GENE EBITDA is ‪−464.84 K‬ PLN, and current EBITDA margin is −7.44%. See more stats in READ-GENE financial statements.
Like other stocks, RDG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade READ-GENE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So READ-GENE technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating READ-GENE stock shows the buy signal. See more of READ-GENE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.